In the randomised phase 3 ACE-Breast-02 trial, ARX788 significantly prolonged PFS in HER2-positive advanced breast cancer (11.3 months vs. 8.2 months, HR = 0.64, P = 0.0006) when compared with lapatinib plus capecitabine, underscoring its therapeutic potential.15 Here, ERBB2 is linked to breast cancer.